The global Hepatitis B Vaccination market size was valued at US$ 1125 million in 2024 and is forecast to a readjusted size of USD 1244 million by 2031 with a CAGR of 1.5% during review period.
Hepatitis B vaccine is a vaccine that prevents hepatitis B. The first dose is recommended within 24 hours of birth with either two or three more doses given after that. This includes those with poor immune function such as from HIV/AIDS and those born premature. It is also recommended that health-care workers be vaccinated. In healthy people routine immunization results in more than 95% of people being protected.
The hepatitis B vaccination market is driven by the increasing focus on disease prevention and the rising awareness of the importance of immunization. Hepatitis B vaccines provide essential protection against the hepatitis B virus (HBV), which can cause chronic liver infections and increase the risk of liver cirrhosis and cancer. The rise in the prevalence of hepatitis B infections and the need for effective control of the disease contribute to market growth as vaccination plays a crucial role in reducing transmission and preventing complications. Moreover, advancements in vaccine technology, such as the development of combination vaccines and birth dose administration, have improved vaccine accessibility and coverage. However, the market also faces challenges, including vaccine supply limitations and the need for ongoing public health initiatives to address barriers to vaccination, such as vaccine hesitancy and lack of awareness. Additionally, ensuring equitable access to hepatitis B vaccines and increasing vaccination rates in high-risk populations can pose obstacles for comprehensive disease prevention. To succeed, companies must focus on research and development to offer innovative and affordable hepatitis B vaccines, collaborate with healthcare providers and governments to implement vaccination programs, and address the challenges to meet the increasing demand for effective and accessible protection against hepatitis B.
This report is a detailed and comprehensive analysis for global Hepatitis B Vaccination market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Hepatitis B Vaccination market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Hepatitis B Vaccination market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Hepatitis B Vaccination market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2020-2031
Global Hepatitis B Vaccination market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2020-2025
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Hepatitis B Vaccination
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Hepatitis B Vaccination market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include GSK, NCPC, Merck, Bio Kangtai, Dynavax, Hissen, KM Biologics, LG Life Sciences, Serum Institute, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
麻豆原创 Segmentation
Hepatitis B Vaccination market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segment by Type
Yeast Derived
CHO Derived
麻豆原创 segment by Application
Children
Adult
Major players covered
GSK
NCPC
Merck
Bio Kangtai
Dynavax
Hissen
KM Biologics
LG Life Sciences
Serum Institute
麻豆原创 segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Hepatitis B Vaccination product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Hepatitis B Vaccination, with price, sales quantity, revenue, and global market share of Hepatitis B Vaccination from 2020 to 2025.
Chapter 3, the Hepatitis B Vaccination competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Hepatitis B Vaccination breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2020 to 2031.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2020 to 2031.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2020 to 2025.and Hepatitis B Vaccination market forecast, by regions, by Type, and by Application, with sales and revenue, from 2026 to 2031.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Hepatitis B Vaccination.
Chapter 14 and 15, to describe Hepatitis B Vaccination sales channel, distributors, customers, research findings and conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.
1 麻豆原创 Overview
1.1 Product Overview and Scope
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 麻豆原创 Analysis by Type
1.3.1 Overview: Global Hepatitis B Vaccination Consumption Value by Type: 2020 Versus 2024 Versus 2031
1.3.2 Yeast Derived
1.3.3 CHO Derived
1.4 麻豆原创 Analysis by Application
1.4.1 Overview: Global Hepatitis B Vaccination Consumption Value by Application: 2020 Versus 2024 Versus 2031
1.4.2 Children
1.4.3 Adult
1.5 Global Hepatitis B Vaccination 麻豆原创 Size & Forecast
1.5.1 Global Hepatitis B Vaccination Consumption Value (2020 & 2024 & 2031)
1.5.2 Global Hepatitis B Vaccination Sales Quantity (2020-2031)
1.5.3 Global Hepatitis B Vaccination Average Price (2020-2031)
2 Manufacturers Profiles
2.1 GSK
2.1.1 GSK Details
2.1.2 GSK Major Business
2.1.3 GSK Hepatitis B Vaccination Product and Services
2.1.4 GSK Hepatitis B Vaccination Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.1.5 GSK Recent Developments/Updates
2.2 NCPC
2.2.1 NCPC Details
2.2.2 NCPC Major Business
2.2.3 NCPC Hepatitis B Vaccination Product and Services
2.2.4 NCPC Hepatitis B Vaccination Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.2.5 NCPC Recent Developments/Updates
2.3 Merck
2.3.1 Merck Details
2.3.2 Merck Major Business
2.3.3 Merck Hepatitis B Vaccination Product and Services
2.3.4 Merck Hepatitis B Vaccination Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.3.5 Merck Recent Developments/Updates
2.4 Bio Kangtai
2.4.1 Bio Kangtai Details
2.4.2 Bio Kangtai Major Business
2.4.3 Bio Kangtai Hepatitis B Vaccination Product and Services
2.4.4 Bio Kangtai Hepatitis B Vaccination Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.4.5 Bio Kangtai Recent Developments/Updates
2.5 Dynavax
2.5.1 Dynavax Details
2.5.2 Dynavax Major Business
2.5.3 Dynavax Hepatitis B Vaccination Product and Services
2.5.4 Dynavax Hepatitis B Vaccination Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.5.5 Dynavax Recent Developments/Updates
2.6 Hissen
2.6.1 Hissen Details
2.6.2 Hissen Major Business
2.6.3 Hissen Hepatitis B Vaccination Product and Services
2.6.4 Hissen Hepatitis B Vaccination Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.6.5 Hissen Recent Developments/Updates
2.7 KM Biologics
2.7.1 KM Biologics Details
2.7.2 KM Biologics Major Business
2.7.3 KM Biologics Hepatitis B Vaccination Product and Services
2.7.4 KM Biologics Hepatitis B Vaccination Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.7.5 KM Biologics Recent Developments/Updates
2.8 LG Life Sciences
2.8.1 LG Life Sciences Details
2.8.2 LG Life Sciences Major Business
2.8.3 LG Life Sciences Hepatitis B Vaccination Product and Services
2.8.4 LG Life Sciences Hepatitis B Vaccination Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.8.5 LG Life Sciences Recent Developments/Updates
2.9 Serum Institute
2.9.1 Serum Institute Details
2.9.2 Serum Institute Major Business
2.9.3 Serum Institute Hepatitis B Vaccination Product and Services
2.9.4 Serum Institute Hepatitis B Vaccination Sales Quantity, Average Price, Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
2.9.5 Serum Institute Recent Developments/Updates
3 Competitive Environment: Hepatitis B Vaccination by Manufacturer
3.1 Global Hepatitis B Vaccination Sales Quantity by Manufacturer (2020-2025)
3.2 Global Hepatitis B Vaccination Revenue by Manufacturer (2020-2025)
3.3 Global Hepatitis B Vaccination Average Price by Manufacturer (2020-2025)
3.4 麻豆原创 Share Analysis (2024)
3.4.1 Producer Shipments of Hepatitis B Vaccination by Manufacturer Revenue ($MM) and 麻豆原创 Share (%): 2024
3.4.2 Top 3 Hepatitis B Vaccination Manufacturer 麻豆原创 Share in 2024
3.4.3 Top 6 Hepatitis B Vaccination Manufacturer 麻豆原创 Share in 2024
3.5 Hepatitis B Vaccination 麻豆原创: Overall Company Footprint Analysis
3.5.1 Hepatitis B Vaccination 麻豆原创: Region Footprint
3.5.2 Hepatitis B Vaccination 麻豆原创: Company Product Type Footprint
3.5.3 Hepatitis B Vaccination 麻豆原创: Company Product Application Footprint
3.6 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
4.1 Global Hepatitis B Vaccination 麻豆原创 Size by Region
4.1.1 Global Hepatitis B Vaccination Sales Quantity by Region (2020-2031)
4.1.2 Global Hepatitis B Vaccination Consumption Value by Region (2020-2031)
4.1.3 Global Hepatitis B Vaccination Average Price by Region (2020-2031)
4.2 North America Hepatitis B Vaccination Consumption Value (2020-2031)
4.3 Europe Hepatitis B Vaccination Consumption Value (2020-2031)
4.4 Asia-Pacific Hepatitis B Vaccination Consumption Value (2020-2031)
4.5 South America Hepatitis B Vaccination Consumption Value (2020-2031)
4.6 Middle East & Africa Hepatitis B Vaccination Consumption Value (2020-2031)
5 麻豆原创 Segment by Type
5.1 Global Hepatitis B Vaccination Sales Quantity by Type (2020-2031)
5.2 Global Hepatitis B Vaccination Consumption Value by Type (2020-2031)
5.3 Global Hepatitis B Vaccination Average Price by Type (2020-2031)
6 麻豆原创 Segment by Application
6.1 Global Hepatitis B Vaccination Sales Quantity by Application (2020-2031)
6.2 Global Hepatitis B Vaccination Consumption Value by Application (2020-2031)
6.3 Global Hepatitis B Vaccination Average Price by Application (2020-2031)
7 North America
7.1 North America Hepatitis B Vaccination Sales Quantity by Type (2020-2031)
7.2 North America Hepatitis B Vaccination Sales Quantity by Application (2020-2031)
7.3 North America Hepatitis B Vaccination 麻豆原创 Size by Country
7.3.1 North America Hepatitis B Vaccination Sales Quantity by Country (2020-2031)
7.3.2 North America Hepatitis B Vaccination Consumption Value by Country (2020-2031)
7.3.3 United States 麻豆原创 Size and Forecast (2020-2031)
7.3.4 Canada 麻豆原创 Size and Forecast (2020-2031)
7.3.5 Mexico 麻豆原创 Size and Forecast (2020-2031)
8 Europe
8.1 Europe Hepatitis B Vaccination Sales Quantity by Type (2020-2031)
8.2 Europe Hepatitis B Vaccination Sales Quantity by Application (2020-2031)
8.3 Europe Hepatitis B Vaccination 麻豆原创 Size by Country
8.3.1 Europe Hepatitis B Vaccination Sales Quantity by Country (2020-2031)
8.3.2 Europe Hepatitis B Vaccination Consumption Value by Country (2020-2031)
8.3.3 Germany 麻豆原创 Size and Forecast (2020-2031)
8.3.4 France 麻豆原创 Size and Forecast (2020-2031)
8.3.5 United Kingdom 麻豆原创 Size and Forecast (2020-2031)
8.3.6 Russia 麻豆原创 Size and Forecast (2020-2031)
8.3.7 Italy 麻豆原创 Size and Forecast (2020-2031)
9 Asia-Pacific
9.1 Asia-Pacific Hepatitis B Vaccination Sales Quantity by Type (2020-2031)
9.2 Asia-Pacific Hepatitis B Vaccination Sales Quantity by Application (2020-2031)
9.3 Asia-Pacific Hepatitis B Vaccination 麻豆原创 Size by Region
9.3.1 Asia-Pacific Hepatitis B Vaccination Sales Quantity by Region (2020-2031)
9.3.2 Asia-Pacific Hepatitis B Vaccination Consumption Value by Region (2020-2031)
9.3.3 China 麻豆原创 Size and Forecast (2020-2031)
9.3.4 Japan 麻豆原创 Size and Forecast (2020-2031)
9.3.5 South Korea 麻豆原创 Size and Forecast (2020-2031)
9.3.6 India 麻豆原创 Size and Forecast (2020-2031)
9.3.7 Southeast Asia 麻豆原创 Size and Forecast (2020-2031)
9.3.8 Australia 麻豆原创 Size and Forecast (2020-2031)
10 South America
10.1 South America Hepatitis B Vaccination Sales Quantity by Type (2020-2031)
10.2 South America Hepatitis B Vaccination Sales Quantity by Application (2020-2031)
10.3 South America Hepatitis B Vaccination 麻豆原创 Size by Country
10.3.1 South America Hepatitis B Vaccination Sales Quantity by Country (2020-2031)
10.3.2 South America Hepatitis B Vaccination Consumption Value by Country (2020-2031)
10.3.3 Brazil 麻豆原创 Size and Forecast (2020-2031)
10.3.4 Argentina 麻豆原创 Size and Forecast (2020-2031)
11 Middle East & Africa
11.1 Middle East & Africa Hepatitis B Vaccination Sales Quantity by Type (2020-2031)
11.2 Middle East & Africa Hepatitis B Vaccination Sales Quantity by Application (2020-2031)
11.3 Middle East & Africa Hepatitis B Vaccination 麻豆原创 Size by Country
11.3.1 Middle East & Africa Hepatitis B Vaccination Sales Quantity by Country (2020-2031)
11.3.2 Middle East & Africa Hepatitis B Vaccination Consumption Value by Country (2020-2031)
11.3.3 Turkey 麻豆原创 Size and Forecast (2020-2031)
11.3.4 Egypt 麻豆原创 Size and Forecast (2020-2031)
11.3.5 Saudi Arabia 麻豆原创 Size and Forecast (2020-2031)
11.3.6 South Africa 麻豆原创 Size and Forecast (2020-2031)
12 麻豆原创 Dynamics
12.1 Hepatitis B Vaccination 麻豆原创 Drivers
12.2 Hepatitis B Vaccination 麻豆原创 Restraints
12.3 Hepatitis B Vaccination Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
13.1 Raw Material of Hepatitis B Vaccination and Key Manufacturers
13.2 Manufacturing Costs Percentage of Hepatitis B Vaccination
13.3 Hepatitis B Vaccination Production Process
13.4 Industry Value Chain Analysis
14 Shipments by Distribution Channel
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 Hepatitis B Vaccination Typical Distributors
14.3 Hepatitis B Vaccination Typical Customers
15 Research Findings and Conclusion
16 Appendix
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
GSK
NCPC
Merck
Bio Kangtai
Dynavax
Hissen
KM Biologics
LG Life Sciences
Serum Institute
听
听
*If Applicable.
